Stivarga Regulatory Post-Marketing Surveillance Study in Korea

Stivarga® Regulatory Post-Marketing Surveillance Study in Korea

To investigate and collect post-marketing data on the safety of Stivarga in real world practice in its registered indication(s) as required by Health Authority.

• Inclusion Criteria:
• Signed and dated informed consent
• Patients diagnosed with histologically confirmed metastatic colorectal cancer and/or metastatic or unresectable locally advanced gastrointestinal stromal tumors and/or HCC who have been previously treated with sorafenib by physician
• Patients who are prescribed with Stivarga tablet 40mg(Regorafenib) for the first time
• Exclusion Criteria:
• Patients participating in an investigational program with interventions outside of routine clinical practice
• All contra-indications according to the local marketing authorization have to be considered.